Defendant

Sun Pharma

1 case as defendant.

Cases
1
Active
0
1 closed
Filed
—
Top venue
D N J
1 case

Company profile

Company overview. Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai (Sun House, Goregaon East). It was founded in 1983 by Dilip Shanghvi and was converted into a public limited company in 1993. It is publicly listed on the NSE (SUNPHARMA) and BSE (524715); the Shanghvi family holds roughly 54% of equity. Reported FY25 revenue was about ₹52,578 crore (~US$6bn), with FY26 revenue of ₹58,462 crore and over 47,000 employees. It describes itself as India's largest pharmaceutical company.

Products / services. Sun Pharma is an operating company, not an assertion entity. Its business spans innovative/specialty medicines (dermatology, ophthalmology, onco-dermatology — e.g., Ilumya/tildrakizumab, Cequa, and more recently Leqselvi and Unloxcyt), branded generics, plain generics, active pharmaceutical ingredients (400+ API products), and consumer healthcare. It manufactures tablets, capsules, injectables, creams, ointments and sprays across roughly 40 facilities and sells in more than 100 countries, with the US and India its largest markets. Growth has come partly through acquisitions, including Ranbaxy (2015), Concert Pharmaceuticals (2023), Checkpoint Therapeutics (2025) and the completed buy-in of Taro Pharmaceutical Industries (2024).

Patent-litigation posture. In the tracked data Sun Pharma appears only as a defendant (0 plaintiff, 1 defendant), consistent with an operating company defending infringement claims rather than asserting patents. The single tracked matter, Celgene Corporation v. Sun Pharmaceutical Industries et al. (D.N.J.), is a Hatch-Waxman ANDA dispute over generic lenalidomide (Revlimid®). D.N.J. is the standard venue for such cases against Celgene/Bristol Myers Squibb, which are based in New Jersey — not a plaintiff-friendly NPE venue.

Notable context. Sun filed an ANDA with Paragraph IV certifications in May 2018; Celgene sued in July 2018, then brought a second 2019 action asserting additional non-Orange-Book polymorph patents. The court denied Sun's motion to dismiss for lack of §271(e)(2) subject-matter jurisdiction in April 2020, holding that neither Orange Book listing nor a Paragraph IV certification is required. The parties settled in June 2021 on a licensed generic entry schedule.